15-Deoxy-Δ12,14-prostaglandin J2 Regulates Endogenous Cot MAPK Kinase Kinase 1 Activity Induced by Lipopolysaccharide

Abstract

Cot is a MAPK kinase kinase that has been implicated in cellular activation and proliferation. Here, we show that the addition of lipopolysaccharide (LPS) to RAW264 macrophages induces a 10-fold increase of endogenous Cot activity, measured as MAPK kinase kinase 1 activity. Taxol, but not phorbol 12-myristate 13-acetate (PMA), induces a similar activation of Cot. A tyrosine kinase activity is involved in Cot activation by LPS. 15-Deoxy-Δ12,14-prostaglandin J2, but not rosiglitazone, blocks Cot activation by LPS. Furthermore, 15-deoxy-Δ12,14-prostaglandin J2 also inhibited the LPS-induced Cot in vitro. However, 15-deoxy-Δ12,14-prostaglandin J2 does not inhibit MAPK kinase 1 or ERK1/ERK2 activation/phosphorylation induced by PMA and mediated by c-Raf. Considering these data, we propose that the inhibition of LPS-induced Cot activation is one mechanism by which 15-deoxy-Δ12,14-prostaglandin J2 acts as an anti-inflammatory. Cot is a MAPK kinase kinase that has been implicated in cellular activation and proliferation. Here, we show that the addition of lipopolysaccharide (LPS) to RAW264 macrophages induces a 10-fold increase of endogenous Cot activity, measured as MAPK kinase kinase 1 activity. Taxol, but not phorbol 12-myristate 13-acetate (PMA), induces a similar activation of Cot. A tyrosine kinase activity is involved in Cot activation by LPS. 15-Deoxy-Δ12,14-prostaglandin J2, but not rosiglitazone, blocks Cot activation by LPS. Furthermore, 15-deoxy-Δ12,14-prostaglandin J2 also inhibited the LPS-induced Cot in vitro. However, 15-deoxy-Δ12,14-prostaglandin J2 does not inhibit MAPK kinase 1 or ERK1/ERK2 activation/phosphorylation induced by PMA and mediated by c-Raf. Considering these data, we propose that the inhibition of LPS-induced Cot activation is one mechanism by which 15-deoxy-Δ12,14-prostaglandin J2 acts as an anti-inflammatory. Lipopolysaccharide (LPS) 1The abbreviations used are: LPSlipopolysaccharideERKextracellular signal-regulated kinaseFBSfetal bovine serumGö6850bisindolylmaleimide IHerb Aherbimycin A15d-PGJ215-deoxy-Δ12,14-prostaglandin J2PGE2prostaglandin E2MAPKmitogen-activated protein kinaseMKK1MAPK kinase 1MKKKMAPK kinase kinasePI3Kphosphatidylinositol 3-kinasePKCprotein kinase CPMAphorbol 12-myristate 13-acetatePPAR-γperoxisome proliferator-activated receptor-γTNF-αtumor necrosis factor α.1The abbreviations used are: LPSlipopolysaccharideERKextracellular signal-regulated kinaseFBSfetal bovine serumGö6850bisindolylmaleimide IHerb Aherbimycin A15d-PGJ215-deoxy-Δ12,14-prostaglandin J2PGE2prostaglandin E2MAPKmitogen-activated protein kinaseMKK1MAPK kinase 1MKKKMAPK kinase kinasePI3Kphosphatidylinositol 3-kinasePKCprotein kinase CPMAphorbol 12-myristate 13-acetatePPAR-γperoxisome proliferator-activated receptor-γTNF-αtumor necrosis factor α. is a major cell wall component of Gram-negative bacteria that potently activates macrophages, inducing the production and secretion of immunoregulators such as TNF-α, interleukin-1β, and arachidonic acid metabolites (for reviews see Refs. 1Ulevitch R.J. Tobias P.S. Curr. Opin. Immunol. 1999; 11: 19-22Crossref PubMed PubMed Curr. Opin. PubMed of the secretion of these is and such as a to the the of a to the in the the R.J. Tobias P.S. Curr. Opin. Immunol. 1999; 11: 19-22Crossref PubMed PubMed Curr. Opin. PubMed Immunol. PubMed activation of the an that the and and the (for a see PubMed the tyrosine of and the activation of protein kinase the MAPK PubMed PubMed PubMed Immunol. PubMed However, the mechanism by which activates the signal-regulated 1 and and in the MAPK is not a MAPK kinase kinase that in to of MAPK to activation of the and PubMed PubMed 1999; PubMed 1999; PubMed PubMed PubMed However, that macrophages not ERK1/ERK2 in to the activation of kinase and MAPK the as in PubMed that the MAPK in is one of the that MAPK kinase 1 in and in a of the of the Cot or the of activity 11: PubMed the of the 11: PubMed PubMed 11: PubMed of Cot in PubMed and 1999; PubMed of Cot in induces the activation of protein 1 1999; PubMed PubMed PubMed Immunol. PubMed PubMed 1999; PubMed PubMed 1999; PubMed PubMed and Immunol. PubMed of Cot in the secretion of in and macrophages PubMed PubMed and in the secretion of in has also been Immunol. PubMed Furthermore, Cot an in inducing of the PubMed PubMed Cot is a component in the activation of and that increase the of Cot that the of Cot protein the of PubMed PubMed we that increase the activity of endogenous and Furthermore, we that Cot is the that activates and and in macrophages in to these also that 15-deoxy-Δ12,14-prostaglandin J2 but not rosiglitazone, blocks the LPS-induced activation of Cot and that also Cot activity in vitro. that LPS-induced Cot activation a proliferator-activated bovine A and a phorbol 12-myristate 13-acetate (PMA), and protein and and by and and used to Cot and in the Cot and protein by the of the of in has been Immunol. and macrophages in a in to macrophages a of the and of in and and of and Taxol, or PMA the in the or to the and to the and A and of Cot and the and the in of 1 1 1 and 1 in and in and and protein by the protein 1 by of cell protein 1 of that been to protein Cot by of cell protein of Cot to protein and to a kinase as PubMed of Cot or activity that of that 1 of protein in 1 by of cell protein to and or a a of protein the the or and Cot but of RAW264 macrophages a activation of endogenous Cot activity activation 10-fold the and the addition of LPS. not the activity of c-Raf. is to LPS-induced activation of macrophages an Immunol. PubMed Immunol. 1999; Immunol. we also the of macrophages Cot and activity. increase the activity of endogenous to a but also to activity but has been that protein kinase the phorbol the activation of the MAPK in a of to the mechanism by which PMA and in of RAW264 PMA activity the increase However, in to or Taxol, PMA not Cot activity that PMA and the MAPK in by of endogenous a that in the the Cot we the that Cot activity by and and and endogenous Cot the cell by and a of the Cot of protein that Cot activation by does not or of endogenous Cot RAW264 macrophages or not Cot cell to or not Cot the in the or of and by by and by one of mechanism Cot activation one or However, of Cot of the of protein 1 or or protein tyrosine not the activity of Cot not the inhibition of or of Cot by not increase Cot activity not we also Cot which the protein tyrosine or However, of these the activity of Cot not these that is that of Cot is the in which of of the of Cot by A is an of protein tyrosine and has been to tyrosine and the activation of ERK1/ERK2 in macrophages PubMed we the that Cot RAW264 A the activation of Cot by or the not the activation of by Furthermore, A inhibited the activation of and ERK1/ERK2 by or but not by PMA also A by or protein tyrosine kinase not to A not A Cot activation by LPS. A and or PMA Cot or or and kinase activity as the 1 to Cot or of the and and a of protein and in of Cot by of and has been that protein kinase which is of induces the of the of Cot and that is by an increase in activation PubMed However, the of RAW264 an of not the of ERK1/ERK2 or or PMA not of an of Cot in not increase the activity of or not the to not kinase has been to a in activation and in the of PubMed Cot also in secretion PubMed PubMed we to the that in activation of the MAPK and of an of and the activation of and However, not the LPS-induced activation of Cot or the of and ERK1/ERK2 that is involved in the activation of Cot by does not inhibit Cot activation by LPS. and or PMA of ERK1/ERK2 and and Cot or measured as to Cot or or one of and the the of the of Cot by of of activation PubMed PubMed Immunol. PubMed 1999; PubMed of RAW264 macrophages a of the activation of Cot by or ERK1/ERK2 by LPS. not the of LPS-induced tyrosine as by not the the activation of the of and ERK1/ERK2 by ERK1/ERK2 activation Cot in RAW264 macrophages and or PMA and the of ERK1/ERK2 and as as Cot or one of and the the of 1 to Cot or RAW264 macrophages or and and Cot activity the of to Cot activity cell Cot or macrophages or kinase activity of the measured in the or of as the to Cot or in the of the of macrophages also to LPS. to not inhibit the LPS-induced activation of Cot Furthermore, we the of rosiglitazone, a an that is to or the of PubMed Cot activation by to does not the the that has been to a activity of PubMed of RAW264 not inhibit LPS-induced activation of Cot that acts a mechanism of the of Cot activity in and the activity of Cot these cell measured in the or of of Cot activity inhibited by of not inhibit Cot activity in not the and in to the inhibition of Cot activity by a in activity in the of in the in we that the activation of macrophages a 10-fold of endogenous kinase activity of Cot. a and is the of activation of ERK1/ERK2 and in PubMed Immunol. PubMed the that by to the activation of ERK1/ERK2 as has been PubMed Immunol. PubMed Immunol. PubMed PubMed 1999; PubMed PubMed PubMed Immunol. PubMed the that does not ERK1/ERK2 in macrophages PubMed Cot to the that activates the MAPK in activation of does not to by the of the of protein protein or protein tyrosine not A acid of the activity 11: PubMed 11: PubMed and has been that Cot by in PubMed PubMed However, Cot that of these the activation of Cot by LPS. However, the of Cot of in macrophages and a and mechanism activity not has been that in is in a the of the of the factor 11: PubMed PubMed and that induces the of Cot 11: PubMed been to in Cot the we used a to a the of which is to the PubMed Cot or Cot. these LPS-induced activation of Cot the of the of or of or Cot. However, does not the activation of Cot in the of Cot one of the Cot of Cot protein kinase in has been to the of the of Cot PubMed kinase is of does not to involved in the activation of Cot and the of the MAPK an of does not Cot activation that inhibit the activation of protein kinase and not the activity of Cot in of or of Cot. the we that of macrophages to inhibit protein tyrosine also inhibited Cot activation by or but not by that in macrophages, the MAPK is by the that blocks the activation of and ERK1/ERK2 by or but not by and by the that blocks the activation of and ERK1/ERK2 by PMA but not by is a of a of that in Curr. Opin. PubMed been implicated in and in inhibit the production of TNF-α, interleukin-1β, in macrophages, or PubMed PubMed Immunol. PubMed PubMed is that the of the not to has been that such as also a mechanism of PubMed PubMed and activity of PubMed Immunol. PubMed and has been that the of the PubMed PubMed that LPS-induced Cot activity in as as in that activity is of rosiglitazone, which does not the the inhibition of LPS-induced Cot the of in has been and is to the of Cot in the of an by the of measured in to 1999; PubMed that to inhibit the activation of Cot in is to the of Cot is or the of mediated by the of Cot as a the in Cot PubMed that Cot a in the LPS-induced activation of the MAPK and in the production of a of and in Cot is an the of inhibition not the activation of the MAPK by and to in and the activation of one or of Lipopolysaccharide (LPS) 1The abbreviations used are: LPSlipopolysaccharideERKextracellular signal-regulated kinaseFBSfetal bovine serumGö6850bisindolylmaleimide IHerb Aherbimycin A15d-PGJ215-deoxy-Δ12,14-prostaglandin J2PGE2prostaglandin E2MAPKmitogen-activated protein kinaseMKK1MAPK kinase 1MKKKMAPK kinase kinasePI3Kphosphatidylinositol 3-kinasePKCprotein kinase CPMAphorbol 12-myristate 13-acetatePPAR-γperoxisome proliferator-activated receptor-γTNF-αtumor necrosis factor α.1The abbreviations used are: LPSlipopolysaccharideERKextracellular signal-regulated kinaseFBSfetal bovine serumGö6850bisindolylmaleimide IHerb Aherbimycin A15d-PGJ215-deoxy-Δ12,14-prostaglandin J2PGE2prostaglandin E2MAPKmitogen-activated protein kinaseMKK1MAPK kinase 1MKKKMAPK kinase kinasePI3Kphosphatidylinositol 3-kinasePKCprotein kinase CPMAphorbol 12-myristate 13-acetatePPAR-γperoxisome proliferator-activated receptor-γTNF-αtumor necrosis factor α. is a major cell wall component of Gram-negative bacteria that potently activates macrophages, inducing the production and secretion of immunoregulators such as TNF-α, interleukin-1β, and arachidonic acid metabolites (for reviews see Refs. 1Ulevitch R.J. Tobias P.S. Curr. Opin. Immunol. 1999; 11: 19-22Crossref PubMed PubMed Curr. Opin. PubMed of the secretion of these is and such as a to the the of a to the in the the R.J. Tobias P.S. Curr. Opin. Immunol. 1999; 11: 19-22Crossref PubMed PubMed Curr. Opin. PubMed Immunol. PubMed activation of the an that the and and the (for a see PubMed the tyrosine of and the activation of protein kinase the MAPK PubMed PubMed PubMed Immunol. PubMed However, the mechanism by which activates the signal-regulated 1 and and in the MAPK is not lipopolysaccharide signal-regulated kinase bovine A 15-deoxy-Δ12,14-prostaglandin J2 protein kinase MAPK kinase 1 MAPK kinase kinase protein kinase phorbol 12-myristate 13-acetate proliferator-activated necrosis factor α. lipopolysaccharide signal-regulated kinase bovine A 15-deoxy-Δ12,14-prostaglandin J2 protein kinase MAPK kinase 1 MAPK kinase kinase protein kinase phorbol 12-myristate 13-acetate proliferator-activated necrosis factor α. a MAPK kinase kinase that in to of MAPK to activation of the and PubMed PubMed 1999; PubMed 1999; PubMed PubMed PubMed However, that macrophages not ERK1/ERK2 in to the activation of kinase and MAPK the as in PubMed that the MAPK in is one of the that MAPK kinase 1 in and in a of the of the Cot or the of activity 11: PubMed the of the 11: PubMed PubMed 11: PubMed of Cot in PubMed and 1999; PubMed of Cot in induces the activation of protein 1 1999; PubMed PubMed PubMed Immunol. PubMed PubMed 1999; PubMed PubMed 1999; PubMed PubMed and Immunol. PubMed of Cot in the secretion of in and macrophages PubMed PubMed and in the secretion of in has also been Immunol. PubMed Furthermore, Cot an in inducing of the PubMed PubMed Cot is a component in the activation of and that increase the of Cot that the of Cot protein the of PubMed PubMed we that increase the activity of endogenous and Furthermore, we that Cot is the that activates and and in macrophages in to these also that 15-deoxy-Δ12,14-prostaglandin J2 but not rosiglitazone, blocks the LPS-induced activation of Cot and that also Cot activity in vitro. that LPS-induced Cot activation a proliferator-activated bovine A and a phorbol 12-myristate 13-acetate (PMA), and protein and and by and and used to Cot and in the Cot and protein by the of the of in has been Immunol. and macrophages in a in to macrophages a of the and of in and and of and Taxol, or PMA the in the or to the and to the and A and of Cot and the and the in of 1 1 1 and 1 in and in and and protein by the protein 1 by of cell protein 1 of that been to protein Cot by of cell protein of Cot to protein and to a kinase as PubMed of Cot or activity that of that 1 of protein in 1 by of cell protein to and or a a of protein the the or bovine A and a phorbol 12-myristate 13-acetate (PMA), and protein and and by and and used to Cot and in the Cot and protein by the of the of in has been Immunol. and macrophages in a in to macrophages a of the and of in and and of and Taxol, or PMA the in the or to the and to the and A and of Cot and the and the in of 1 1 1 and 1 in and in and and protein by the protein 1 by of cell protein 1 of that been to protein Cot by of cell protein of Cot to protein and to a kinase as PubMed of Cot or activity that of that 1 of protein in 1 by of cell protein to and or a a of protein the the or and Cot but of RAW264 macrophages a activation of endogenous Cot activity activation 10-fold the and the addition of LPS. not the activity of c-Raf. is to LPS-induced activation of macrophages an Immunol. PubMed Immunol. 1999; Immunol. we also the of macrophages Cot and activity. increase the activity of endogenous to a but also to activity but has been that protein kinase the phorbol the activation of the MAPK in a of to the mechanism by which PMA and in of RAW264 PMA activity the increase However, in to or Taxol, PMA not Cot activity that PMA and the MAPK in by of endogenous a that in the the Cot we the that Cot activity by and and and endogenous Cot the cell by and a of the Cot of protein that Cot activation by does not or mechanism Cot activation one or However, of Cot of the of protein 1 or or protein tyrosine not the activity of Cot not the inhibition of or of Cot by not increase Cot activity not we also Cot which the protein tyrosine or However, of these the activity of Cot not these that is that of Cot is the in which of of the of Cot by A is an of protein tyrosine and has been to tyrosine and the activation of ERK1/ERK2 in macrophages PubMed we the that Cot RAW264 A the activation of Cot by or the not the activation of by Furthermore, A inhibited the activation of and ERK1/ERK2 by or but not by PMA also A by or protein tyrosine kinase not to A not A Cot activation by LPS. A and or PMA Cot or or and kinase activity as the 1 to Cot or of the and and a of protein and in of Cot by of and has been that protein kinase which is of induces the of the of Cot and that is by an increase in activation PubMed However, the of RAW264 an of not the of ERK1/ERK2 or or PMA not of an of Cot in not increase the activity of or not the to not kinase has been to a in activation and in the of PubMed Cot also in secretion PubMed PubMed we to the that in activation of the MAPK and of an of and the activation of and However, not the LPS-induced activation of Cot or the of and ERK1/ERK2 that is involved in the activation of Cot by does not inhibit Cot activation by LPS. and or PMA of ERK1/ERK2 and and Cot or measured as to Cot or or one of and the the of the of Cot by of of activation PubMed PubMed Immunol. PubMed 1999; PubMed of RAW264 macrophages a of the activation of Cot by or ERK1/ERK2 by LPS. not the of LPS-induced tyrosine as by not the the activation of the of and ERK1/ERK2 by ERK1/ERK2 activation Cot in RAW264 macrophages and or PMA and the of ERK1/ERK2 and as as Cot or one of and the the of 1 to Cot or RAW264 macrophages or and and Cot activity the of to Cot activity cell Cot or macrophages or kinase activity of the measured in the or of as the to Cot or in the of the of macrophages also to LPS. to not inhibit the LPS-induced activation of Cot Furthermore, we the of rosiglitazone, a an that is to or the of PubMed Cot activation by to does not the the that has been to a activity of PubMed of RAW264 not inhibit LPS-induced activation of Cot that acts a mechanism of the of Cot activity in and the activity of Cot these cell measured in the or of of Cot activity inhibited by of not inhibit Cot activity in not the and in to the inhibition of Cot activity by a in activity in the of in the in and Cot but of RAW264 macrophages a activation of endogenous Cot activity activation 10-fold the and the addition of LPS. not the activity of c-Raf. is to LPS-induced activation of macrophages an Immunol. PubMed Immunol. 1999; Immunol. we also the of macrophages Cot and activity. increase the activity of endogenous to a but also to activity PMA but has been that protein kinase the phorbol the activation of the MAPK in a of to the mechanism by which PMA and in of RAW264 PMA activity the increase However, in to or Taxol, PMA not Cot activity that PMA and the MAPK in by of endogenous a that in the the Cot we the that Cot activity by and and and endogenous Cot the cell by and a of the Cot of protein that Cot activation by does not or mechanism Cot activation one or However, of Cot of the of protein 1 or or protein tyrosine not the activity of Cot not the inhibition of or of Cot by not increase Cot activity not we also Cot which the protein tyrosine or However, of these the activity of Cot not these that is that of Cot is the in which of activity. of the of Cot by A is an of protein tyrosine and has been to tyrosine and the activation of ERK1/ERK2 in macrophages PubMed we the that Cot RAW264 A the activation of Cot by or the not the activation of by Furthermore, A inhibited the activation of and ERK1/ERK2 by or but not by PMA also A by or protein tyrosine kinase not to A not of Cot by of and has been that protein kinase which is of induces the of the of Cot and that is by an increase in activation PubMed However, the of RAW264 an of not the of ERK1/ERK2 or or PMA not of an of Cot in not increase the activity of or not the to not kinase has been to a in activation and in the of PubMed Cot also in secretion PubMed PubMed we to the that in activation of the MAPK and of an of and the activation of and However, not the LPS-induced activation of Cot or the of and ERK1/ERK2 that is involved in the activation of Cot by LPS. the of Cot by of of activation PubMed PubMed Immunol. PubMed 1999; PubMed of RAW264 macrophages a of the activation of Cot by or ERK1/ERK2 by LPS. not the of LPS-induced tyrosine as by not the the activation of the of and ERK1/ERK2 by the of macrophages also to LPS. to not inhibit the LPS-induced activation of Cot Furthermore, we the of rosiglitazone, a an that is to or the of PubMed Cot activation by to does not the the that has been to a activity of PubMed of RAW264 not inhibit LPS-induced activation of Cot that acts a mechanism of the of Cot activity in and the activity of Cot these cell measured in the or of of Cot activity inhibited by of not inhibit Cot activity in not the and in to the inhibition of Cot activity by a in activity in the of in the in we that the activation of macrophages a 10-fold of endogenous kinase activity of Cot. a and is the of activation of ERK1/ERK2 and in PubMed Immunol. PubMed the that by to the activation of ERK1/ERK2 as has been PubMed Immunol. PubMed Immunol. PubMed PubMed 1999; PubMed PubMed PubMed Immunol. PubMed the that does not ERK1/ERK2 in macrophages PubMed Cot to the that activates the MAPK in activation of does not to by the of the of protein protein or protein tyrosine not A acid of the activity 11: PubMed 11: PubMed and has been that Cot by in PubMed PubMed However, Cot that of these the activation of Cot by LPS. However, the of Cot of in macrophages and a and mechanism activity not has been that in is in a the of the of the factor 11: PubMed PubMed and that induces the of Cot 11: PubMed been to in Cot the we used a to a the of which is to the PubMed Cot or Cot. these LPS-induced activation of Cot the of the of or of or Cot. However, does not the activation of Cot in the of Cot one of the Cot of Cot protein kinase in has been to the of the of Cot PubMed kinase is of does not to involved in the activation of Cot and the of the MAPK an of does not Cot activation that inhibit the activation of protein kinase and not the activity of Cot in of or of Cot. the we that of macrophages to inhibit protein tyrosine also inhibited Cot activation by or but not by that in macrophages, the MAPK is by the that blocks the activation of and ERK1/ERK2 by or but not by and by the that blocks the activation of and ERK1/ERK2 by PMA but not by is a of a of that in Curr. Opin. PubMed been implicated in and in inhibit the production of TNF-α, interleukin-1β, in macrophages, or PubMed PubMed Immunol. PubMed PubMed is that the of the not to has been that such as also a mechanism of PubMed PubMed and activity of PubMed Immunol. PubMed and has been that the of the PubMed PubMed that LPS-induced Cot activity in as as in that activity is of rosiglitazone, which does not the the inhibition of LPS-induced Cot the of in has been and is to the of Cot in the of an by the of measured in to 1999; PubMed that to inhibit the activation of Cot in is to the of Cot is or the of mediated by the of Cot as a the in Cot PubMed that Cot a in the LPS-induced activation of the MAPK and in the production of a of and in Cot is an the of inhibition not the activation of the MAPK by and to in and the activation of one or of we that the activation of macrophages a 10-fold of endogenous kinase activity of Cot. a and is the of activation of ERK1/ERK2 and in PubMed Immunol. PubMed the that by to the activation of ERK1/ERK2 as has been PubMed Immunol. PubMed Immunol. PubMed PubMed 1999; PubMed PubMed PubMed Immunol. PubMed the that does not ERK1/ERK2 in macrophages PubMed Cot to the that activates the MAPK in LPS-induced activation of does not to by the of the of protein protein or protein tyrosine not A acid of the activity 11: PubMed 11: PubMed and has been that Cot by in PubMed PubMed However, Cot that of these the activation of Cot by LPS. However, the of Cot of in macrophages and a and mechanism activity not has been that in is in a the of the of the factor 11: PubMed PubMed and that induces the of Cot 11: PubMed been to in Cot the we used a to a the of which is to the PubMed Cot or Cot. these LPS-induced activation of Cot the of the of or of or Cot. However, does not the activation of Cot in the of Cot one of the Cot of Cot protein kinase in has been to the of the of Cot PubMed kinase is of does not to involved in the activation of Cot and the of the MAPK an of does not Cot activation that inhibit the activation of protein kinase and not the activity of Cot in of or of Cot. the we that of macrophages to inhibit protein tyrosine also inhibited Cot activation by or but not by that in macrophages, the MAPK is by the that blocks the activation of and ERK1/ERK2 by or but not by and by the that blocks the activation of and ERK1/ERK2 by PMA but not by LPS. is a of a of that in Curr. Opin. PubMed been implicated in and in inhibit the production of TNF-α, interleukin-1β, in macrophages, or PubMed PubMed Immunol. PubMed PubMed is that the of the not to has been that such as also a mechanism of PubMed PubMed and activity of PubMed Immunol. PubMed and has been that the of the PubMed PubMed that LPS-induced Cot activity in as as in that activity is of rosiglitazone, which does not the the inhibition of LPS-induced Cot the of in has been and is to the of Cot in the of an by the of measured in to 1999; PubMed that to inhibit the activation of Cot in is to the of Cot is or the of mediated by the of Cot as a the in Cot PubMed that Cot a in the LPS-induced activation of the MAPK and in the production of a of and in Cot is an the of inhibition not the activation of the MAPK by and to in and the activation of one or of the Cot also